Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

PAX5 (Paired Box 5)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

FusionPlex™ Pan-Heme panel

SureSeq™ Pan-Myeloid Panel

FusionPlex™ Pan-Heme panel

SureSeq™ Pan-Myeloid Panel

›

PAX5 overexpression	Diffuse Large B Cell Lymphoma	PAX5 overexpression	Diffuse Large B Cell Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
PAX5 fusion	Childhood B Acute Lymphoblastic Leukemia	PAX5 fusion	Childhood B Acute Lymphoblastic Leukemia	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
PAX5 mutation	Acute Lymphocytic Leukemia	PAX5 mutation	Acute Lymphocytic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
IKZF1 deletion + PAX5 deletion	Acute Lymphocytic Leukemia	IKZF1 deletion + PAX5 deletion	Acute Lymphocytic Leukemia	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3	dasatinib + blinatumomab Sensitive: C3 – Early Trials dasatinib + blinatumomab Sensitive : C3
PAX5 mutation	Diffuse Large B Cell Lymphoma	PAX5 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3
PAX5 overexpression	Prostate Cancer	PAX5 overexpression	Prostate Cancer	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3	niraparib Sensitive: C3 – Early Trials niraparib Sensitive : C3
CD20 expression + PAX5 expression + BCL2 expression	Marginal Zone Lymphoma	CD20 expression + PAX5 expression + BCL2 expression	Marginal Zone Lymphoma	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	CHZ868 Sensitive: D – Preclinical CHZ868 Sensitive : D	CHZ868 Sensitive: D – Preclinical CHZ868 Sensitive : D
PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	carfilzomib Sensitive: D – Preclinical carfilzomib Sensitive : D	carfilzomib Sensitive: D – Preclinical carfilzomib Sensitive : D
PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	PAX5-JAK2 fusion	B Acute Lymphoblastic Leukemia	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D	bortezomib Sensitive: D – Preclinical bortezomib Sensitive : D